ORIL is a public, unlisted Australian company that has identified and developed a family of plant-based compounds with a novel membrane-mediated mode of action. This innovative mode of action addresses the heterogeneity of tumours and causes all forms of cancer cells to self destruct whilst not affecting normal cells.
ORIL’s first-in-class compounds have been shown to have potent in vitro and in vivo inhibitory activity for a wide range of cancer cell lines, with no untoward toxicity.
ORIL believes this innovative therapeutic approach will provide a new, effective and powerful weapon in the clinician’s armoury, not only in the war against cancer, but potentially against other diseases.
ORIL’s lead compound, ORIL007, is in late-preclinical testing with first-in-man Phase I studies planned for the 3rd quarter of 2013.
The research and development program is balanced with ORIL’s strategy of creating value by protecting its intellectual property through patents.
The company is currently funded by private equity, through its shareholder base, to Phase I and is seeking a strategic investment/partner to commercialise its asset.
Registered Office
Oncology Research International Limited
Level 5, 45 St George Terrace,
Perth WA 6000 Australia